Literature DB >> 28780294

Pathophysiology and immunological profile of myasthenia gravis and its subgroups.

Fredrik Romi1, Yu Hong2, Nils Erik Gilhus3.   

Abstract

Myasthenia gravis (MG) is an autoimmune antibody-mediated disease characterized by muscle weakness and fatigability. It is believed that the initial steps triggering humoral immunity in MG take place inside thymic tissue and thymoma. The immune response against one or several epitopes expressed on thymic tissue cells spills over to neuromuscular junction components sharing the same epitope causing humoral autoimmunity and antibody production. The main cause of MG is acetylcholine receptor antibodies. However, many other neuromuscular junction membrane protein targets, intracellular and extracellular proteins are suggested to participate in MG pathophysiology. MG should be divided into subgroups based on clinical presentation and immunology. This includes onset age, clinical characteristics, thymic pathology and antibody profile. The immunological profile of these subgroups is determined by the antibodies present.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28780294     DOI: 10.1016/j.coi.2017.07.006

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  19 in total

1.  Thymoma mimicking an aortic aneurysm: always expect the unexpected.

Authors:  Dario Michaux; Lawek Berzenji; Lotte Keulen; Inez Rodrigus
Journal:  BMJ Case Rep       Date:  2019-07-17

2.  Myasthenia gravis and pregnancy: retrospective evaluation of 27 pregnancies in a tertiary center and comparison with previous studies.

Authors:  Atakan Tanacan; Erdem Fadiloglu; Gonca Ozten; Ali Can Gunes; Gokcen Orgul; Mehmet Sinan Beksac
Journal:  Ir J Med Sci       Date:  2019-05-09       Impact factor: 1.568

3.  C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis.

Authors:  Florencia Aguirre; Analisa Manin; Victoria C Fernandez; Mariano E Justo; Juliana Leoni; Mariela L Paz; Andres M Villa
Journal:  Ther Adv Neurol Disord       Date:  2020-08-10       Impact factor: 6.570

Review 4.  Myasthenia gravis and infectious disease.

Authors:  Nils Erik Gilhus; Fredrik Romi; Yu Hong; Geir Olve Skeie
Journal:  J Neurol       Date:  2018-01-25       Impact factor: 4.849

Review 5.  Advances in autoimmune myasthenia gravis management.

Authors:  Shuhui Wang; Iva Breskovska; Shreya Gandhy; Anna Rostedt Punga; Jeffery T Guptill; Henry J Kaminski
Journal:  Expert Rev Neurother       Date:  2018-07-04       Impact factor: 4.618

Review 6.  Long Non-Coding RNAs in the Cell Fate Determination of Neoplastic Thymic Epithelial Cells.

Authors:  Alessia Iaiza; Claudia Tito; Federica Ganci; Andrea Sacconi; Enzo Gallo; Silvia Masciarelli; Giulia Fontemaggi; Alessandro Fatica; Enrico Melis; Vincenzo Petrozza; Federico Venuta; Mirella Marino; Giovanni Blandino; Francesco Fazi
Journal:  Front Immunol       Date:  2022-04-22       Impact factor: 8.786

Review 7.  Immunopathogenesis in Myasthenia Gravis and Neuromyelitis Optica.

Authors:  Zhen Wang; Yaping Yan
Journal:  Front Immunol       Date:  2017-12-12       Impact factor: 7.561

8.  Myasthenia gravis as a prognostic marker in patients with thymoma.

Authors:  Bernardo Cacho-Díaz; Karen Salmerón-Moreno; Nydia A Lorenzana-Mendoza; Julia Texcocano; Oscar Arrieta
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

9.  Eculizumab improved weakness and taste disorder in thymoma-associated generalized myasthenia gravis with anti-striational antibodies: A case report.

Authors:  Eiichiro Amano; Shinichi Otsu; Shigeaki Suzuki; Akira Machida
Journal:  eNeurologicalSci       Date:  2019-01-07

10.  CXCR5-negative natural killer cells ameliorate experimental autoimmune myasthenia gravis by suppressing follicular helper T cells.

Authors:  Chun-Lin Yang; Peng Zhang; Ru-Tao Liu; Na Zhang; Min Zhang; Heng Li; Tong Du; Xiao-Li Li; Ying-Chun Dou; Rui-Sheng Duan
Journal:  J Neuroinflammation       Date:  2019-12-29       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.